Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

A Phase 1/2 Study of a ROR1-Targeting CAR T Cell Therapy (ONCT-808) in Adult Patients with Relapsed/Refractory (R/R) Aggressive B Cell Lymphomas (BCL)

Michael Wang, Patrick Connor Johnson, Salim Yazji, Yisrael Katz, Angela Pietrofeso, James Robinson, Matthew Mei, Matthew J. Frigault, James B. Breitmeyer, Caron A. Jacobson

Blood (2024) 144 (Supplement 1): 1743.

https://doi.org/10.1182/blood-2024-200998

Published: 2024

Journal Articles

A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 459.

https://doi.org/10.1182/blood-2024-204113

Published: 2024

Journal Articles

The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin

Blood (2024) 144 (Supplement 1): 652.

https://doi.org/10.1182/blood-2024-202153

Published: 2024

Journal Articles

Outpatient Administration of Brexucabtagene Autoleucel (brexu-cel) for Acute Lymphoblastic Leukemia (ALL) and Mantle Cell Lymphoma (MCL) Is Safe and Feasible

Tamer Othman, John H. Baird, Yan Wang, Stacy Pak, Ibrahim Aldoss, Ji-Lian Cai, Alexey Danilov, Tycel J. Phillips, Vaibhav Agrawal, Karamjeet S Sandhu, Matthew Mei, Paul B. Koller, Joycelynne Michelle Palmer, Stephen J. Forman, Lihua E. Budde, Ahmed Aribi

Blood (2024) 144 (Supplement 1): 2278.

https://doi.org/10.1182/blood-2024-207085

Published: 2024

Journal Articles

Investigating the Novel Combination of the Innate Cell Engager (ICE®) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK® in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study

Joseph Maakaron, Dipenkumar Modi, Matthew Mei, Tatyana Feldman, Gunjan L. Shah, Amitkumar N. Mehta, Craig S. Sauter, Rashmi Khanal, Stefan K. Barta, Michael Emig, Lydia Wunderle, Andre Overesch, Alexandra Vasile, Jennifer Rubel, Thorsten Graef, Heather Raymon, Alison Moskowitz

Blood (2024) 144 (Supplement 1): 3052.

https://doi.org/10.1182/blood-2024-193896

Published: 2024

Journal Articles

A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001) and Orthogonal IL-2 (STK-009) in Subjects with Relapsed or Refractory CD19 Expressing Hematologic Malignancies (NCT05665062)

Maria Lia Palomba, Paolo F. Caimi, Matthew Mei, Francisco Hernandez-Ilizaliturri, Geoffrey Shouse, Allison M. Winter, Greg Yedinak, David Mou, Nestor Huang, Anna Moua, Martin Oft, Paul-Joseph Aspuria, Anita Mehta-Damani, Naiyer Rizvi, Sherry Unabia, Peg Taylor, Jeffrey McLeroy, Matthew J Cortese

Blood (2024) 144 (Supplement 1): 3453.

https://doi.org/10.1182/blood-2024-202090

Published: 2024

Journal Articles

Clonal Hematopoiesis Is Associated with Non-Myeloid Subsequent Malignant Neoplasms after Autologous Hematopoietic Cell Transplantation

June-Wha Rhee, Sitong Chen, Raju Pillai, Alysia Bosworth, Artem Oganesyan, Liezl Atencio, Caitlyn Estrada, Mareen Kassabian, Lanie Lindenfeld, Scott R. Goldsmith, Michael Rosenzweig, Alex F. Herrera, Matthew Mei, Ryotaro Nakamura, F. Lennie Wong, Stephen J. Forman, Saro Armenian

Blood (2024) 144 (Supplement 1): 947.

https://doi.org/10.1182/blood-2024-200402

Published: 2024

Journal Articles

A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 1742.1.

https://doi.org/10.1182/blood-2024-198727

Published: 2024

Journal Articles

Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Vs-Host Disease and Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation: A Case-Control Propensity Matching Analysis

Blood (2024) 144 (Supplement 1): 3534.

https://doi.org/10.1182/blood-2024-207125

Published: 2024

Journal Articles

Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade

Blood (2023) 142 (16): 1359–1370.

https://doi.org/10.1182/blood.2023020485

Published: 2023

Includes: Supplemental data

Journal Articles

The next frontier: enter PD-1 and exit PET scans?

Matthew Mei, Alex F. Herrera

Blood (2023) 141 (21): 2545–2546.

https://doi.org/10.1182/blood.2023020326

Published: 2023

Journal Articles

Updated Results and Correlative Analysis: Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)

Sairah Ahmed, Ian W. Flinn, Matthew Mei, Peter A. Riedell, Philippe Armand, Natalie S. Grover, Renu Balyan, Cliff Ding, Aung Myo, Ivan D. Horak, Helen E. Heslop

Blood (2022) 140 (Supplement 1): 7496–7497.

https://doi.org/10.1182/blood-2022-158869

Published: 2022

Journal Articles

A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses

Blood (2022) 140 (Supplement 1): 9446–9447.

https://doi.org/10.1182/blood-2022-167173

Published: 2022

Journal Articles

Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Blood (2022) 140 (Supplement 1): 10568–10570.

https://doi.org/10.1182/blood-2022-163652

Published: 2022

Journal Articles

Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Blood (2022) 140 (Supplement 1): 4821–4822.

https://doi.org/10.1182/blood-2022-164639

Published: 2022

Journal Articles

Nivolumab Plus ICE As First Salvage Therapy in High-Risk Relapsed/Refractory Hodgkin Lymphoma

Matthew Mei, Joycelynne Palmer, Ni-Chun Tsai, Hun Ju Lee, Iris Isufi, Leslie L. Popplewell, Lynne Smith, Lacolle Peters, Lara Rodriguez, James Godfrey, John H. Baird, Joo Y. Song, Steven T. Rosen, Larry W. Kwak, Stephen J Forman, Alex F. Herrera

Blood (2022) 140 (Supplement 1): 774–776.

https://doi.org/10.1182/blood-2022-167626

Published: 2022

Journal Articles

Myeloablative Vs Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation in Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

Blood (2022) 140 (Supplement 1): 12819–12820.

https://doi.org/10.1182/blood-2022-164657

Published: 2022

Journal Articles

Interim Results of a Phase 1/2 Study of Pembrolizumab Combined with Blinatumomab in Patients with Relapsed/Refractory (r/r) ALL

Blood (2022) 140 (Supplement 1): 8985–8986.

https://doi.org/10.1182/blood-2022-170279

Published: 2022

Journal Articles

Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma

Blood (2022) 140 (Supplement 1): 6531–6533.

https://doi.org/10.1182/blood-2022-159823

Published: 2022

Journal Articles

Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial)

David M. Kurtz, Sairah Ahmed, Cheuk Ka Tong, Matthew Mei, Cliff Ding, Ian W. Flinn, Peter A. Riedell, Gregory J. Hogan, Andre Schultz, Jacob J. Chabon, Helen E. Heslop, Aung Myo, Ash A. Alizadeh, Ivan D. Horak

Blood (2022) 140 (Supplement 1): 2378–2380.

https://doi.org/10.1182/blood-2022-162150

Published: 2022

NARROW

A Phase 1/2 Study of a ROR1-Targeting CAR T Cell Therapy (ONCT-808) in Adult Patients with Relapsed/Refractory (R/R) Aggressive B Cell Lymphomas (BCL)

A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma

The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin

Outpatient Administration of Brexucabtagene Autoleucel (brexu-cel) for Acute Lymphoblastic Leukemia (ALL) and Mantle Cell Lymphoma (MCL) Is Safe and Feasible

Investigating the Novel Combination of the Innate Cell Engager (ICE®) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK® in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study

A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001) and Orthogonal IL-2 (STK-009) in Subjects with Relapsed or Refractory CD19 Expressing Hematologic Malignancies (NCT05665062)

Clonal Hematopoiesis Is Associated with Non-Myeloid Subsequent Malignant Neoplasms after Autologous Hematopoietic Cell Transplantation

A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Vs-Host Disease and Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation: A Case-Control Propensity Matching Analysis

Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade

The next frontier: enter PD-1 and exit PET scans?

Updated Results and Correlative Analysis: Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)

A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses

Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Nivolumab Plus ICE As First Salvage Therapy in High-Risk Relapsed/Refractory Hodgkin Lymphoma

Myeloablative Vs Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation in Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

Interim Results of a Phase 1/2 Study of Pembrolizumab Combined with Blinatumomab in Patients with Relapsed/Refractory (r/r) ALL

Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma

Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only